Collegium Pharmaceutical operates as a specialty neuroscience commercial-stage company built around an established pain franchise and a refreshed central nervous system portfolio. The product roster generated $393.4M of net product revenue across the first six months of 2026. The second quarter alone booked $199.9M of net product revenue, expanding at a low single-digit pace even as GAAP profitability compressed under acquisition-related costs. Strategic intent now visibly tilts the portfolio toward higher-growth central nervous system assets. The Corium Therapeutics deal completed in May 2026 marks the clearest expression of that direction.
Operational execution over the trailing twelve months reflects a company in transition rather than distress. Jornay PM revenue grew $13.4M in the second quarter on higher volume and improved gross-to-net dynamics. Belbuca held a positive trajectory on stronger pricing and demand. Xtampza ER and the Nucynta Products contracted modestly as branded Nucynta faced authorized-generic dilution. Azstarys layered in $12.9M of incremental revenue in a partial quarter, providing early evidence of integration momentum and immediate diversification away from opioid-class exposure. Net loss of $15.1M in the quarter contrasts with $12.0M of net income a year earlier, reflecting acquisition transaction expenses rather than underlying demand erosion.
The balance sheet, post-Corium, carries heavy but actively managed leverage against a stable equity base. The acceleration of capital return was announced in August 2026. The transaction took the form of a $50.0M accelerated share repurchase, with the initial delivery priced at $25.70 per share. The move underlines management’s view that intrinsic value exceeds recent price action. Operating cash flow before working capital movements sustains the deleveraging arc and the capital return cadence. The portfolio now combines an established pain franchise with a refreshed central nervous system growth engine. The strategic question is whether integration discipline converts that engine into durable margin expansion across 2027 and beyond.